US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

36.99

-0.2900-0.78%

Post-market: 36.990.00000.00%19:30 EDT

Volume:388.89K

Turnover:14.44M

Market Cap:1.19B

PE:-12.38

High:38.82

Open:37.72

Low:36.75

Close:37.28

52wk High:50.16

52wk Low:14.32

Shares:32.26M

Float Shares:21.62M

Volume Ratio:0.82

T/O Rate:1.80%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:3.59

PE(LYR):-11.81

Loading ...

Overview Company News Filings

Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs

TherapeuticsMD Q2 License Revenue Falls; Continues to Evaluate Strategic Alternatives

LB Pharmaceuticals Q2 Loss Per Share Narrows

MT Newswires Live

Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities

Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss

MT Newswires Live

LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

Benzinga Earnings

LB Pharmaceuticals Q2 FY26 Net Loss Widens to $51.6 Million

Lb Pharmaceuticals Inc Q2 Basic EPS USD -1.71

THOMSON REUTERS

Lb Pharmaceuticals Inc Q2 Pretax Profit USD -51.603 Million

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals management to meet with Piper Sandler

LB Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

LB Pharmaceuticals Prices USD 150 Million Private Placement at USD 34.94 Per Share

Lb Pharmaceuticals - Net Proceeds to Fund Lb-102 Pipeline Expansion and General Corporate Purposes

THOMSON REUTERS

Lb Pharmaceuticals Announces $150 Million Private Placement

THOMSON REUTERS

LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained

LB Pharmaceuticals Releases Update on Nova-2 Phase 3 Schizophrenia Trial Timeline

Lb Pharmaceuticals - Topline Data from Phase 2 Trial in Adjunctive Mdd Expected in H1 2029

THOMSON REUTERS

Lb Pharmaceuticals - Expects Cash Runway into Q2 2029

THOMSON REUTERS

Lb Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 Nova-2 Trial of Lb-102 in Schizophrenia

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/LBRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":36.99,"timestamp":1790971200000,"preClose":37.28,"halted":0,"volume":388885,"hourTrading":{"tag":"盘后","latestPrice":36.99,"preClose":36.99,"latestTime":"19:30 EDT","volume":2661,"amount":98430.39,"timestamp":1790983804912,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007778969957081522,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Closed","change":-0.29,"latestTime":"10-02 16:00:00 EDT","open":37.72,"high":38.815,"low":36.75,"amount":14443570.007299999,"amplitude":0.055392,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":5,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":37.28,"postHourTrading":{"tag":"盘后","latestPrice":36.99,"preClose":36.99,"latestTime":"19:30 EDT","volume":2661,"amount":98430.39,"timestamp":1790983804912,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.822858,"impliedVol":1.0903,"impliedVolPercentile":0.9432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":0.822858,"shares":32259175,"dividePrice":0,"high":38.815,"amplitude":0.055392,"preClose":37.28,"low":36.75,"week52Low":14.3166,"pbRate":"3.59","week52High":50.16,"institutionHeld":0,"latestPrice":36.99,"eps":-2.988,"divideRate":0,"volume":388885,"delay":0,"ttmEps":-2.988,"open":37.72,"prevYearClose":22.26,"prevWeekClose":37.33,"prevMonthClose":38.38,"prevQuarterClose":38.38,"fiveDayClose":37.33,"twentyDayClose":47.52,"sixtyDayClose":33.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-10-01","current":-12.379518,"percent":0.829545,"low":-37.407457,"twenty":-31.692493,"median":-23.786169,"eighty":-16.200178,"high":-0.410019,"avg":-23.53712,"sd":7.556968,"marketCap":1238107136},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-28","current":-18.029899,"twenty":-31.988483,"median":-24.686825,"eighty":-17.939919,"marketCap":1544891890},{"date":"2026-09-04","current":-17.890599,"twenty":-31.950812,"median":-24.595973,"eighty":-17.81229,"marketCap":1532955996},{"date":"2026-09-11","current":-17.412462,"twenty":-31.886233,"median":-24.257328,"eighty":-17.792713,"marketCap":1491986843},{"date":"2026-09-18","current":-15.865106,"twenty":-31.84587,"median":-23.934856,"eighty":-17.412462,"marketCap":1359401634},{"date":"2026-09-25","current":-14.231158,"twenty":-31.724783,"median":-23.892916,"eighty":-16.881618,"marketCap":1219396815},{"date":"2026-10-01","current":-14.44952,"twenty":-31.692493,"median":-23.786169,"eighty":-16.200178,"marketCap":1238107136}],"updateTime":1790999807084},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658948040","title":"Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948040?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479023,"startTime":"0","endTime":"0","summary":"Inhibikase Q2 net loss widens on higher R&D, SG&A costsOverviewU.S. clinical-stage pharma's Q2 net loss widened yr/yr on higher R&D and SG&A costsCompany raised $50 mln in July via share sale to RA Ca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SGMT","LBRX","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948753","title":"TherapeuticsMD Q2 License Revenue Falls; Continues to Evaluate Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948753","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948753?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:09","pubTimestamp":1786478962,"startTime":"0","endTime":"0","summary":"TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternativesOverviewUS pharmaceutical royalty company's Q2 license revenue declined yr/yr due to lower licensed product salesNe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENTA","BK4139","LBRX","TXMD","BK4198","XTNT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658186299","title":"LB Pharmaceuticals Q2 Loss Per Share Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2658186299","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658186299?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:40","pubTimestamp":1786452000,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals  reported Tuesday that its Q2 net loss per share narrowed to $1.71, from a loss of $13.58 per share a year earlier.Analysts polled by FactSet expected a loss of $0.80 per share.As of June 30, the company had $327.8 million in cash, cash equivalents and marketable securities.It said this balance excludes net proceeds from a $150 million private placement completed in July and, based on its current operating assumptions, expects to fund operations beyond Q2 2029.The company's net loss widened to $51.6 million from $4.9 million a year earlier, as research and development expenses rose sharply, primarily due to its Phase 3 schizophrenia trial.LB Pharmaceuticals also said it now expects topline data from that trial in the first half of 2027, earlier than previously forecast.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4233","BK4213","BK4007","LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658791868","title":"Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2658791868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658791868?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:39","pubTimestamp":1786451965,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences Q2 loss widens on warrant liabilitiesOverviewUS specialty pharma firm's Q2 net loss and loss per share missed analyst expectationsQ2 net loss includes $48.7 mln non-cash charge f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1803068623.USD","LU0823416689.USD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","ACHV","LU1061106388.HKD","LU1815333072.USD","LU0208291251.USD","IE00BQXX3C00.GBP","HRTS","FMED","SCYX","TMO","LU2041044095.USD","LU1720051108.HKD","LU2264538146.SGD","IE00BJJMRZ35.SGD","LU2764262908.HKD","LU1670628061.USD","LU0640476718.USD","IE0002141913.USD","LU0528227936.USD","LU0957791311.USD","LU2468319806.SGD","BK4585","IE0009355771.USD","LU0234572021.USD","LU1983299246.USD","LU2125909247.SGD","LU1057294990.SGD","IE00BQXX3D17.EUR","LU1712237335.SGD","LU0882574055.USD","LU0342679015.USD","LU1623119135.USD","LU2063271972.USD","LU0122379950.USD","LU2543165471.USD","LU1923621640.USD","LU2764263039.SGD","TMED","IE00B19Z8W00.USD","GNMX","LU0096362180.USD","LU1633808545.USD","LU1854104046.USD","LU1153585028.USD","BK4121","BK4548","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658909169","title":"Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658909169","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658909169?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:09","pubTimestamp":1786450182,"startTime":"0","endTime":"0","summary":"Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990574","title":"LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990574","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990574?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:05","pubTimestamp":1786449920,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61105422/lb-pharmaceuticals-q2-eps-1-71-misses-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399087","title":"LB Pharmaceuticals Q2 FY26 Net Loss Widens to $51.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399087","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658399087?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:02","pubTimestamp":1786449776,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Q2 FY26 net loss widens to $51.6 millionLB Pharmaceuticals posted a Q2 net loss of USD 51.6 million, widening from USD 4.9 million a year earlier.R&D costs climbed to USD 44.1 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8jr1Jr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","BK4007","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LBRX","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997706","title":"Lb Pharmaceuticals Inc Q2 Basic EPS USD -1.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997706?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX2ZR14F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997047","title":"Lb Pharmaceuticals Inc Q2 Pretax Profit USD -51.603 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997047?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX2ZR14F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990834","title":"Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990834?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"evaluating the efficacy and safety of LB-102 in patients with acute. Company expects to schedule a pre-NDA meeting with the FDA thereafter in. -- The 52-week open-label safety and tolerability trial , evaluating. the long-term safety and tolerability of LB-102 in patients with stable. schizophrenia, is enrolling eligible patients who have c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","LB","BK4007","BK4213","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956102","title":"LB Pharmaceuticals management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956102?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:00","pubTimestamp":1786392021,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on August 17 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4233","BK4213","LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656024378","title":"LB Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2656024378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656024378?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:42","pubTimestamp":1785753720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655886045","title":"LB Pharmaceuticals Prices USD 150 Million Private Placement at USD 34.94 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2655886045","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655886045?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:20","pubTimestamp":1785327655,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per shareLB Pharmaceuticals priced a USD 150 million private placement of common stock and pre-funded warrants with institution","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL74y1xn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867089","title":"Lb Pharmaceuticals - Net Proceeds to Fund Lb-102 Pipeline Expansion and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655867089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:00","pubTimestamp":1785326402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA6VXJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655290867","title":"Lb Pharmaceuticals Announces $150 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2655290867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655290867?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:00","pubTimestamp":1785326402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA6VXJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653721485","title":"LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2653721485","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653721485?lang=en_us&edition=fundamental","pubTime":"2026-07-23 23:25","pubTimestamp":1784820335,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lb-pharmaceuticals-buy-rating-reaffirmed-on-lb-102-clinical-momentum-and-regulatory-progress-45-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lb-pharmaceuticals-buy-rating-reaffirmed-on-lb-102-clinical-momentum-and-regulatory-progress-45-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653875778","title":"LB Pharmaceuticals Releases Update on Nova-2 Phase 3 Schizophrenia Trial Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2653875778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653875778?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:04","pubTimestamp":1784721878,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timelineLB Pharmaceuticals posted a press release accelerating expected topline timing for Phase 3 NOVA-2 data for LB-102 in sc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL7Nm80f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LBRX","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","BK4007","IE00BGHQF748.EUR","SG9999014013.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757466","title":"Lb Pharmaceuticals - Topline Data from Phase 2 Trial in Adjunctive Mdd Expected in H1 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757466?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757457","title":"Lb Pharmaceuticals - Expects Cash Runway into Q2 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757457?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757430","title":"Lb Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 Nova-2 Trial of Lb-102 in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757430?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":82,"code":"91000000","status":"200"}]}}